LLY

906.48

-1.97%↓

UNH

577.95

-2%↓

NVO

131.97

-3.67%↓

JNJ

167.31

+0.18%↑

MRK

118.26

+0.13%↑

LLY

906.48

-1.97%↓

UNH

577.95

-2%↓

NVO

131.97

-3.67%↓

JNJ

167.31

+0.18%↑

MRK

118.26

+0.13%↑

LLY

906.48

-1.97%↓

UNH

577.95

-2%↓

NVO

131.97

-3.67%↓

JNJ

167.31

+0.18%↑

MRK

118.26

+0.13%↑

LLY

906.48

-1.97%↓

UNH

577.95

-2%↓

NVO

131.97

-3.67%↓

JNJ

167.31

+0.18%↑

MRK

118.26

+0.13%↑

LLY

906.48

-1.97%↓

UNH

577.95

-2%↓

NVO

131.97

-3.67%↓

JNJ

167.31

+0.18%↑

MRK

118.26

+0.13%↑

Strona główna・Stock List・AbbVie Inc

AbbVie Inc

Closed

Sector Healthcare

193.29 -1.3

Buy Sell

Overview

Share price change

24h

Current

Min

191.81

Max

195.91

Key metrics
By Trading Economics
Income	1M 1.4B
Sales	2.2B 14B
P/E Sector Avg	51.05 103.001
EPS	2.65
Profit margin	9.474
Employees	50,000
EBITDA	514M 5B

Recommendations
By TipRanks
Recommendations	Buy
12 Months Forecast	+1.96 upside

Dividends
By Dow Jones
Next Earnings	25 paź 2024
Next Dividend date	15 lis 2024
Next Ex Dividend date	15 paź 2024

Market Stats
By TradingEconomics
Market Cap	-549M 345B
Previous open	194.59
Previous close	193.29

News Sentiment

By Acuity

67%

33%

304 / 365 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Bearish Evidence

194.74 / 197.01 Support & Resistance

AbbVie Inc Chart

Past performance is not a reliable indicator of future results.

Related News

25 lip 2024, 12:18 UTC

Earnings

AbbVie 2Q Revenue Gets Boost From Skyrizi, Rinvoq Sales

27 cze 2024, 13:58 UTC

Acquisitions, Mergers, Takeovers

AbbVie Buys Celsius Therapeutics for $250 Million

26 kwi 2024, 20:53 UTC

Major Market Movers

AbbVie Shares Close Down 4.6%, Sees Additional Humira Volume Erosion in 2Q

26 kwi 2024, 12:25 UTC

Earnings

AbbVie Lifts Outlook After 1Q Revenue Unexpectedly Rises

3 wrz 2024, 04:00 UTC

Top News

Novo, Amgen, Other Pharma Stocks Have Clinical Trials That Could Send Them Soaring -- Barrons.com

12 sie 2024, 14:30 UTC

Acquisitions, Mergers, Takeovers

Correction to Big Drugmakers Are Clinching Smaller Deals Article -- WSJ

12 sie 2024, 09:30 UTC

Top News

Acquisitions, Mergers, Takeovers

Big Drugmakers Are Clinching Smaller Deals -- WSJ

1 sie 2024, 12:23 UTC

Acquisitions, Mergers, Takeovers

AbbVie Completes Acquisition Of Cerevel Therapeutics >ABBV CERE

29 lip 2024, 10:30 UTC

Top News

Big Pharma Rallies and Moves Past Obesity -- Heard on the Street -- WSJ

25 lip 2024, 13:01 UTC

Earnings

AbbVie Slides Despite Beating Second-Quarter Views, Raising Guidance -- IBD

25 lip 2024, 12:46 UTC

Top News

Earnings

AbbVie Stock Is Rising on Strong Earnings. CEO Cites 'Significant Momentum.' -- Barrons.com

25 lip 2024, 11:36 UTC

Earnings

AbbVie Sees FY Adj EPS $10.71-Adj EPS $10.91 >ABBV

25 lip 2024, 11:36 UTC

Earnings

AbbVie 2Q Global Net Rev From Oncology Portfolio $1.63B >ABBV

25 lip 2024, 11:36 UTC

Earnings

AbbVie 2Q EPS 77c >ABBV

25 lip 2024, 11:36 UTC

Earnings

AbbVie 2Q Rev $14.46B >ABBV

25 lip 2024, 11:36 UTC

Earnings

AbbVie 2Q Global Skyrizi Rev $2.73B >ABBV

25 lip 2024, 11:36 UTC

Earnings

AbbVie 2Q U.S. HUMIRA Rev $2.36B >ABBV

25 lip 2024, 11:36 UTC

Earnings

AbbVie 2Q International HUMIRA Rev $454M >ABBV

25 lip 2024, 11:36 UTC

Earnings

AbbVie 2Q Adj EPS $2.65 >ABBV

25 lip 2024, 11:36 UTC

Earnings

AbbVie 2Q Net $1.37B >ABBV

25 lip 2024, 11:36 UTC

Earnings

AbbVie 2Q Global IMBRUVICA Rev $833M >ABBV

25 lip 2024, 08:40 UTC

Top News

These Stocks Are Moving the Most Today: Ford, Tesla, Alphabet, Nvidia, Super Micro, IBM, ServiceNow, Chipotle, and More -- Barrons.com

27 cze 2024, 13:28 UTC

Acquisitions, Mergers, Takeovers

AbbVie Acquires Celsius for $250 Million in Cash >ABBV

27 cze 2024, 13:28 UTC

Acquisitions, Mergers, Takeovers

AbbVie: Celsius' Lead Asset Has Completed Phase 1 Study in Inflammatory Bowel Disease >ABBV

27 cze 2024, 13:26 UTC

Acquisitions, Mergers, Takeovers

AbbVie Acquires Celsius Therapeutics >ABBV

23 maj 2024, 20:05 UTC

Acquisitions, Mergers, Takeovers

AbbVie Completes Acquisition Of Landos Biopharma >ABBV LABP

7 maj 2024, 20:30 UTC

Top News

Teva Earnings Are Soon. What Could Keep the Stock Gains Going. -- Barrons.com

26 kwi 2024, 13:03 UTC

Earnings

AbbVie Beats First-Quarter Views As Skyrizi Looks To Take Humira's Title -- IBD

26 kwi 2024, 12:04 UTC

Earnings

AbbVie Raises Earnings Guidance Even as Humira Sales Continue to Drop -- Barrons.com

26 kwi 2024, 11:41 UTC

Earnings

AbbVie 1Q Adjusted EPS Cut 8c by Acquired IPR&D, Milestones Expense >ABBV

Peer Comparison

Price change

AbbVie Inc Forecast

Price Target

By TipRanks

1.96% upside

12 Months Forecast

Average 199.57 USD 1.96%

High 218 USD

Low 170 USD

Based on 15 Wall Street analysts offering 12 month price targets forAbbVie Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

15 ratings

Buy

Hold

Sell

Based on 15 analysts giving stock ratings to AbbVie Inc - Dist in the past 3 months.

Technical Score

By Trading Central

194.74 / 197.01Support & Resistance

Recent bearish events outweigh bullish events.

Bullish events outweigh bearish events.

There is one bullish event.

Sentiment

By Acuity

304 / 365 Ranking in Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About AbbVie Inc

AbbVie Inc. (AbbVie) is a research-based biopharmaceutical company. The Company is engaged in research and development, manufacturing, commercialization and sale of medicines and therapies. AbbVie offers its products in various therapeutic categories, including Immunology products, which include Humira, Skyrizi and Rinvoq; Oncology products consists of Imbruvica and Venclexta; Aesthetics products include Botox Cosmetic, Juvederm Collection and other aesthetics; Neuroscience products, such as Botox Therapeutic, Vraylar, Duopa and Duodopa, and Ubrelvy; Eye care products consists of Lumigan, Alphagan and Restasis ; Women's health products incudes Lo Loestrin, Orilissa and other women's health; and Other key products, which includes Mavyret, Creon, Lupron, Linzess and Synthroid. The Company's products are sold worldwide directly to wholesalers, distributors, government agencies, health care facilities and independent retailers from AbbVie-owned distribution centers and public warehouses.